Lannett Company, Inc. (AMEX:LCI)
| CAPS Rating |
|
|---|---|
| Open | $4.95 |
| Previous Close | $4.96 |
| Daily Range | $4.78 - $4.97 |
| 52-Week Range | $3.41 - $5.95 |
| Market Cap | $135.46M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 19,685 |
| Average Daily Volume | 0 |
LCI
VS S&P 500 (SPY)
How do you think LCI will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
LCI Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
LCI News and Commentary
- Prepare your Portfolio: Historical Odds of a Double-Dip Recession Hit 50% – NASDAQ
- Lannett Awaits Three Expected FDA Decisions – SeekingAlpha
- Lannett Awaits 3 Expected FDA Decisions – SeekingAlpha
- Cardium Therapeutics, Lannett: Dealing With Debilitating Biotech Situations – SeekingAlpha
- Analyst Calls: APOL, CEPH, DELL, GCI, GOLD, KSS, LEN, PEET, PM ... – BloggingStocks
- How to Maneuver the Biotech Sector – SeekingAlpha
- Life Sciences Companies Raise Record Amounts of Capital – SeekingAlpha
- Here's How ViroPharma Is Making You So Much Cash – The Motley Fool
- BioSante Attracts Institutional Investors Ahead of Key FDA Catalysts in 2011 – SeekingAlpha
- Will King Pharmaceuticals Whiff on Revenues Next Quarter? – The Motley Fool
- The Big Money Says to Hold Savient Pharmaceuticals – The Motley Fool
- Endo Pharma Expands Into Generic Drugs With Recent Acquisitions – SeekingAlpha
- 10 Year-End Stock Trades on FDA Binary Events – SeekingAlpha
- 2 Year-End FDA Run-Up Stock Plays – SeekingAlpha
- Lannett Reports Stronger 4Q Earnings Despite Revenue Drop – Fox Business
- Lannett Company, Inc.: Warming Up or Cooling Off? – The Motley Fool
- 10 Top Winners Since 9/11 – The Motley Fool
Related News and Articles
- Modified Study, Same Bloody Results – The Motley Fool
RSS Headlines
Fool UK
